Ph.D., Policy Principal, American Cancer Society Cancer Action Network (ACS CAN)
Biography
Dr. Mark Fleury specializes in research, drug development, and regulatory policies along with other science and technology related projects. He has worked extensively on reform of diagnostic testing oversight, helped lead a coalition in 2016 that authored a landscape report on drug development challenges in pediatric cancer, and led another coalition in 2017 that created a report and recommendations focused on overcoming cancer clinical trial enrollment barriers. He currently sits on the steering committee of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study, which examines the use of targeted anticancer agents used off-label in clinical settings. Throughout his work, Mark has striven to incorporate patient perspectives on to inherently science-based issues, advocating for the inclusion of patients as partners throughout the bench to bedside translation of science.
